Emerald Advisers, LLC

How is AI transforming life sciences and medicine? ?? Emerald’s own Dr. Nishit Trivedi , PhD/MBBS/MBA joins YouTube creator, Jacob Rant for an exclusive discussion on AI’s role in drug discovery, patient care, and medical research. From innovation to ethics, explore how AI is shaping the future of healthcare. ?? Tune in now! https://lnkd.in/esrUqmn4 #AI #Healthcare #LifeSciences #Innovation

As we continue our 6 Weeks of Emerald series, this week we feature our Financials Team: Steve Russell, Esq., MBA – (Portfolio Manager & Senior Research Analyst) and Ori Elan – (Vice President). The financial sector is shifting. While banks faced challenges in 2024, those hurdles are now in the past. Success will be driven by deposit growth, earnings expansion, and tangible book value appreciation. Insurance companies had a strong year, with small-cap excess and surplus insurers offering notable opportunities. We believe small regional banks are positioned to outperform, fueled by earnings growth from loan portfolios. Watch our latest video where Steve and Ori break down the trends shaping the sector and what to watch for in 2025: https://lnkd.in/gu7-xfYD #Banking #Insurance #Investing #FinancialGrowth #EmeraldAdvisers

Big news in cancer detection that's changing everything. While traditional methods relied on surgical biopsies, new liquid biopsy technology is transforming patient care through innovation. The meaningful difference? ?? Simple blood draw replacing invasive procedures ?? Earlier detection of various cancers ?? Real-time treatment monitoring ?? Significantly improved patient experience The global liquid biopsy potential tells the story: 2023: $11 Billion 2033: $33 Billion projected This represents just one example of the breakthroughs we're seeing. One innovation. One incredible opportunity. At Emerald, we find these innovations early because we understand both the science and the market potential. Our F/m Emerald Life Sciences Innovation ETF (LFSC) focuses on capturing these breakthrough opportunities. That's the Emerald advantage in life sciences investing. Discover how we identify tomorrow's healthcare leaders in our complete Life Sciences market analysis: https://lnkd.in/drVdAc7F #LifeSciences #Healthcare #Innovation #Investing #Biotech #Investing #ETF

From AI-driven advancements to the impact of a new administration, the Industrial sector is evolving rapidly. How will these changes shape the industry? This week, Emerald’s Industrials Team— Erik Cianci, Peter Garner, and Scott Blumenthal, MBA (Director of Industrials Research)—breaks it all down, sharing expert insights on what’s ahead. ?? Watch the full discussion here: https://lnkd.in/dYC_XgNF At Emerald, we’re always focused on uncovering opportunities in a shifting landscape. Stay tuned for more insights! #Industrials #Investing #AI #EmeraldInsights

Innovation in life sciences requires a different investment approach. Watch @Stacey Sears, Emerald’s Senior Vice President and Portfolio Manager, discuss the FM Emerald Life Sciences Innovation ETF (LFSC) on @Nasdaq's Just for Funds with Head of ETP Listings @Alison Hennessey. What makes LFSC distinctive: Actively managed with small/mid-cap focus Deep fundamental research approach 30+ years of healthcare sector expertise 5-person specialized investment team PhD and MBA expertise combining science and finance The opportunity remains compelling: - Healthcare sector growing above GDP (5% annually) - Unprecedented pace of innovation - 2/3 of clinical trials from small/emerging companies - 56% of new drug approvals from emerging players As Stacey explains: "We believe innovators start small. We're bringing decades of expertise to identify the best opportunities in this dynamic sector." Watch Stacey's full NASDAQ interview: https://lnkd.in/dazruPuM #ETF #Healthcare #Innovation #Investing #BioTech

Let's talk about what's happening in organ transplants. Our recent Life Sciences Innovation white paper examines a critical breakthrough: With 104,506 patients on waiting lists and traditional storage methods falling short, innovation was desperately needed. Then everything changed. New technology now allows: ?? Cross-country organ transport up to 2,000 miles ?? Real-time vitality monitoring during transit ?? Enhanced preservation techniques ?? More lives saved through better matching This is innovation in action at its finest. This is exactly what we look for at Emerald, and this is why active management matters in healthcare investing. Real solutions. Real impact. Real opportunities. Where do you see healthcare innovation making the biggest difference? Read the full innovation analysis: https://lnkd.in/drVdAc7F #LifeSciences #Healthcare #Innovation #Investing #Biotech #Investing #ETF

The life sciences sector isn't just growing - it's transforming. Here's what our expert team revealed in our latest deep dive: Join Emerald Life Science’s Joe W. Garner, Director of Research & Portfolio Manager, and our two leading Directors of Life Sciences Research, Dr. @Nishit Trivedi , PhD/MBBS/MBA and Dr. @Terry Smith, as they unpack the future of life sciences innovation. Key insights from our discussion: The 2003 genome decoding identified over 8,000 genetic diseases Healthcare utilization is rising with aging demographics AI is revolutionizing everything from drug discovery to medical imaging Early disease detection is becoming more sophisticated and accessible Most exciting developments we're tracking: - Revolutionary changes in neurology diagnostics - AI-enhanced mammogram accuracy - Innovations in chronic disease management - Breakthrough organ transplant technologies As Dr. Trivedi notes: "We're seeing applications in utility all the way from drug discovery research and development to taking the compound forward." Watch our full team discussion on the future of life sciences investing: https://lnkd.in/dHxwCYQ7 #LifeSciences #Healthcare #Innovation #Investing #Biotechnology

This week, we’re diving into the future of technology with insights from Emerald’s Tech Team: Steve Amsterdam, Nate Jones, PhD, MBA, and Derek Fisher. From emerging innovations to industry-defining trends, our experts share their key predictions for 2025 and what could shape the year ahead. ?? Watch now: https://lnkd.in/e3navNef #Technology #Innovation #EmergingTrends #Tech2025 #EmeraldAdvisers

Small-Cap Earnings Show Encouraging Trends! Emerald’s Stacey Sears joined CNBC’s “The Squawk Box” to discuss the positive data emerging from small-cap earnings reports. As market conditions evolve, we’re seeing opportunities take shape for long-term investors. Watch the full segment here: https://lnkd.in/er4ErZ9E #SmallCaps #Investing #Markets #EmeraldAdvisers

Think healthcare is expensive now? Let's look at the numbers. As revealed in our latest Life Sciences Innovation white paper, U.S. healthcare reached $4.5 trillion in 2022, and it's projected to hit 19.7% of GDP by 2032. But here's what really matters in this growth: ?? Biotechs launched 53% of new drugs ?? Small companies led 66% of clinical trials ?? Innovation is accelerating faster than ever At Emerald, we're not just watching this growth from the sidelines. We're actively seeking tomorrow's healthcare leaders through our F/m Emerald Life Sciences Innovation ETF (LFSC). With 30+ years of experience and one clear mission, we're focused on finding breakthrough opportunities in this dynamic market. The next decade of healthcare is being built today. Want to learn more about investing in healthcare innovation? Explore our complete healthcare market analysis: https://lnkd.in/drVdAc7F #LifeSciences #Healthcare #Innovation #Investing #Biotech #Investing #ETF